The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 07 04 2021
accepted: 12 05 2021
entrez: 12 7 2021
pubmed: 13 7 2021
medline: 26 10 2021
Statut: epublish

Résumé

Recently, primary immune regulatory disorders have been described as a subset of inborn errors of immunity that are dominated by immune mediated pathology. As the pathophysiology of disease is elucidated, use of biologic modifiers have been increasingly used successfully to treat disease mediated clinical manifestations. Hematopoietic cell transplant (HCT) has also provided definitive therapy in several PIRDs. Although biologic modifiers have been largely successful at treating disease related manifestations, data are lacking regarding long term efficacy, safety, and their use as a bridge to HCT. This review highlights biologic modifiers in the treatment of several PIRDs and there use as a therapeutic bridge to HCT.

Identifiants

pubmed: 34248986
doi: 10.3389/fimmu.2021.692219
pmc: PMC8264452
doi:

Substances chimiques

Biological Products 0
STAT1 Transcription Factor 0
STAT1 protein, human 0
STAT3 Transcription Factor 0
STAT3 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

692219

Informations de copyright

Copyright © 2021 Arnold, Chellapandian and Leiding.

Déclaration de conflit d'intérêts

JL - Consultant for Pharming (manufacturer of leniolisib) and Sobi (manufacturer of emapalumab). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Br J Haematol. 2009 Apr;145(1):101-6
pubmed: 19208097
Front Immunol. 2018 Mar 16;9:543
pubmed: 29599784
J Allergy Clin Immunol. 2018 Nov;142(5):1665-1669
pubmed: 30092289
J Allergy Clin Immunol. 2017 May;139(5):1629-1640.e2
pubmed: 28139313
Science. 2015 Jul 24;349(6246):436-40
pubmed: 26206937
Blood. 2017 Nov 23;130(21):2307-2316
pubmed: 28972011
Curr Opin Immunol. 2017 Dec;49:14-19
pubmed: 28806575
J Allergy Clin Immunol. 2016 Jan;137(1):327-330
pubmed: 26478010
Arthritis Rheum. 2008 Aug;58(8):2443-52
pubmed: 18668535
J Med Genet. 2008 Jan;45(1):15-21
pubmed: 17873118
Blood. 2013 Feb 7;121(6):877-83
pubmed: 23131490
Hum Mutat. 2006 Jan;27(1):62-8
pubmed: 16278825
Nat Genet. 2014 Oct;46(10):1140-6
pubmed: 25217959
Front Pediatr. 2019 Aug 27;7:353
pubmed: 31508401
J Clin Immunol. 2021 May;41(4):769-779
pubmed: 33475942
Int J Hematol. 2020 Aug;112(2):258-262
pubmed: 32180118
N Engl J Med. 2006 Aug 10;355(6):581-92
pubmed: 16899778
Blood. 2016 Mar 31;127(13):1666-75
pubmed: 26825707
Blood. 2019 Nov 21;134(21):1783-1786
pubmed: 31537529
Blood. 2018 Jul 5;132(1):89-100
pubmed: 29632024
Haematologica. 2019 Nov;104(11):2314-2323
pubmed: 30792213
Blood. 2011 Nov 24;118(22):5794-8
pubmed: 21881043
Pediatrics. 2007 Sep;120(3):e622-8
pubmed: 17698967
Blood. 2012 Jun 21;119(25):6016-24
pubmed: 22451424
Blood. 2010 Aug 19;116(7):1079-82
pubmed: 20489057
J Allergy Clin Immunol. 2015 Feb;135(2):551-3
pubmed: 25662309
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
J Allergy Clin Immunol. 2019 Jan;143(1):266-275
pubmed: 29778502
Lancet Haematol. 2019 Dec;6(12):e630-e637
pubmed: 31537486
Blood. 2016 Jun 23;127(25):3154-64
pubmed: 27114460
Pediatr Blood Cancer. 2014 Jun;61(6):1034-40
pubmed: 24470399
J Clin Immunol. 2018 May;38(4):464-467
pubmed: 29796761
Drugs. 2019 Jan;79(1):99-103
pubmed: 30623346
J Allergy Clin Immunol. 2016 Jan;137(1):223-230
pubmed: 26768763
J Allergy Clin Immunol. 2015 Jan;135(1):217-27
pubmed: 25468195
Nat Genet. 2014 Aug;46(8):812-814
pubmed: 25038750
N Engl J Med. 2009 Jun 4;360(23):2416-25
pubmed: 19494217
J Allergy Clin Immunol. 2016 Jul;138(1):210-218.e9
pubmed: 27221134
J Allergy Clin Immunol. 2018 Apr;141(4):1439-1449
pubmed: 28807602
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2379-2386.e5
pubmed: 30995531
J Clin Med. 2020 Oct 17;9(10):
pubmed: 33080915
J Exp Med. 2019 Dec 2;216(12):2778-2799
pubmed: 31601675
Blood. 2011 Jan 6;117(1):53-62
pubmed: 20926771
J Clin Immunol. 2016 Jan;36(1):33-45
pubmed: 26707784
J Clin Immunol. 2019 Jan;39(1):37-44
pubmed: 30543054
Am J Hum Genet. 2012 Jun 8;90(6):986-1001
pubmed: 22608502
J Allergy Clin Immunol. 2020 May;145(5):1452-1463
pubmed: 31887391
J Allergy Clin Immunol. 2018 Feb;141(2):704-717.e5
pubmed: 28601685
Science. 2014 Sep 26;345(6204):1623-1627
pubmed: 25213377
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13765-70
pubmed: 9811875
J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1508-1517
pubmed: 30201097
Blood. 2011 Oct 27;118(17):4577-84
pubmed: 21900192
J Clin Immunol. 2018 Jul;38(5):589-601
pubmed: 29934865
J Med Genet. 2011 May;48(5):343-52
pubmed: 21248318
Reumatol Clin. 2012 Mar-Apr;8(2):78-83
pubmed: 22104048
Clin Infect Dis. 2016 Apr 1;62(7):951-3
pubmed: 26787170
Blood. 2004 Aug 1;104(3):735-43
pubmed: 15069016
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1958-1969.e9
pubmed: 30825606
Blood. 2019 Jul 11;134(2):147-159
pubmed: 31015190
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4
pubmed: 27555459
Lancet. 2004 Nov 13-19;364(9447):1779-85
pubmed: 15541451
Blood. 2015 Jan 22;125(4):591-9
pubmed: 25359994
J Allergy Clin Immunol. 2015 May;135(5):1384-90.e1-8
pubmed: 25539626
Blood. 2017 Dec 21;130(25):2728-2738
pubmed: 28935695
PLoS Med. 2008 Jan 29;5(1):e26
pubmed: 18232731
J Allergy Clin Immunol. 2018 Dec;142(6):1932-1946
pubmed: 29729943
J Allergy Clin Immunol. 2016 Aug;138(2):615-619.e1
pubmed: 27102614
Pediatr Blood Cancer. 2013 Jan;60(1):101-9
pubmed: 22522603
Pediatrics. 2006 Apr;117(4):e743-50
pubmed: 16549504
Blood. 2014 Aug 21;124(8):1331-4
pubmed: 24916509
J Allergy Clin Immunol. 2017 Mar;139(3):1046-1049
pubmed: 27847301
Blood. 2018 Mar 29;131(13):1442-1455
pubmed: 29326099

Auteurs

Danielle E Arnold (DE)

National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

Deepak Chellapandian (D)

Center for Cell and Gene Therapy for Non-Malignant Conditions, Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.

Jennifer W Leiding (JW)

Center for Cell and Gene Therapy for Non-Malignant Conditions, Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, St. Petersburg, FL, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH